

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 2546839 T3**

-
- (51) Int.Cl.: **G 21 G 1/00 (2006.01)** **B 01 D 15/16 (2006.01)** **B 01 D 15/18 (2006.01)**
B 01 D 15/36 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2016-02-08**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2015-11-04**
- (86) Europæisk ansøgning nr.: **12163203.8**
- (86) Europæisk indleveringsdag: **2012-04-04**
- (87) Den europæiske ansøgnings publiceringsdag: **2013-01-16**
- (30) Prioritet: **2011-07-15 DE 102011051868**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **ITM Isotopen Technologien München AG, Lichtenbergstrasse 1, 85748 Garching, Tyskland**
- (72) Opfinder: **ZHERNOSEKOV, Konstantin, Berliner Str. 36, 80805 München, Tyskland**
Marx, Sebastian, Dr., Mainburgerstr.25a, 85356 Freising, Tyskland
Harfensteller, Mark, Berglstraße 2b, 85716 Unterschleißheim, Tyskland
Nikula, Tuomo, Friedrich-Ebert-Straße 16, 85521 Ottobrunn, Tyskland
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **Fremgangsmåde til fremstilling af bærerfrie, ekstremt rene 177Lu-forbindelser samt bærerfrie 177Lu-forbindelser**
- (56) Fremdragne publikationer:
JP-A- 2010 223 827
US-B1- 6 716 353
HASHIMOTO, MATSUOKA, H UCHIDA: "Production of no-carrier-added 177Lu via the 176Yb(n, gamma)177Yb - > 177Lu process", JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, Bd. 255, Nr. 3, 1. März 2003 (2003-03-01), Seiten 575-579, XP002678871, ISSN: 0236-5731

The present invention relates to a method of manufacturing essentially non-carrier-added high-purity ^{177}Lu compounds for medicinal purposes and/or diagnostic purposes in accordance with claim 1 and claim 10, as well as the use of a cation exchange chromatography column for manufacturing high-purity non-carrier-added ^{177}Lu compounds in accordance with claim 12.

Due to promising clinical basic approaches in radionuclide therapy and radionuclide diagnostics there is an increasing worldwide demand for the reactor nuclide ^{177}Lu . As a low-energetic β emitter with a comparatively short half life of $T_{1/2} = 6.71$ days ^{177}Lu constitutes an excellent vehicle for the specific deposition of large amounts of energy in small volumes. These physical properties for the most part are used in form of radioimmuno-radionuclide therapy and peptide receptor radionuclide therapy in oncology, particularly for the treatment and diagnosis of tumors.

As is generally known, ^{177}Lu may be produced by way of the subsequent nuclear reactions:

Direct method: $^{176}\text{Lu}(n,\gamma) ^{177}\text{Lu}$ (1)

Indirect method: $^{176}\text{Yb}(n,\gamma) ^{177}\text{Yb} \rightarrow ^{177}\text{Lu}$ (2)

Nuclear reaction (1) constitutes a neutron capture reaction of ^{176}Lu , which as a last consequence leads to carrier-added ^{177}Lu (^{177}Lu carrier added [^{177}Lu c.a.]) and thus to limited product quality in form of a significantly lower specific activity. As a result, in the marking of biomolecules with ^{177}Lu , the activity bound per quantity of biomolecule is significantly lower. In a limited number of receptors on the surface of the tumor this leads to inferior therapy results or side effects. Through irradiation of ^{176}Lu , the long-lasting metastable radionuclide $^{177\text{m}}\text{Lu}$ ($T_{1/2} = 160.1$ d) is produced additionally, which is undesired in medicinal regards and with regard to radiation protection. Depending on the irradiation parameters, the portion of $^{177\text{m}}\text{Lu}$ may be up to 0.1 % of the ^{177}Lu activity. With regard to the application on humans and in view of the high overall activities to be produced, such contamination is to be regarded critically. Within the scope of the treatments there is a persistent increased risk of

releasing ^{177m}Lu into the environment, which is due to the long half life of the nuclide and the renal excretion of patients treated with Lu isotopes. Thus, the consumer in the hospital faces the problem of the safe handling and disposal of residual amounts of a long-lasting nuclide, which hardly is to be solved by the storage of radioactive waste customary in hospitals.

As was mentioned initially, carrier-added ^{177}Lu , which currently is available on the market, has various disadvantages as opposed to non-carrier-added ^{177}Lu . Due to its being more readily available so far, ^{177}Lu c.a. nevertheless is preferred by many hospitals despite its disadvantages.

The ^{177}Lu which currently is available on the market is essentially marketed by three suppliers. All suppliers produce ^{177}Lu via the same route, i.e. directly from ^{176}Lu via the above-indicated nuclear reaction (1).

This leads to the aforementioned problems.

The more attractive and medicinally and commercially more useful, but technically more demanding option thus is the production of non-carrier-added ^{177}Lu via the indirect nuclear reaction (2). Such a nuclear reaction may be used, for example, on high-flux neutron sources in order to produce carrier-free ^{177}Lu . Through irradiation with ^{176}Yb , the short-life radioisotope ^{177}Yb ($T_{1/2} = 1.9 \text{ h}$) is produced which disintegrates to ^{177}Lu .

In this case, the desired nuclide ^{177}Lu is the nuclide of a different element than the element of the target nuclide ^{176}Yb and therefore may be isolated chemically in a non-carrier-added form (^{177}Lu non carrier added [^{177}Lu n.c.a.]), provided that a quantitative separation of Yb nuclides is possible. Since no ^{177m}Lu occurs by the disintegration of the nuclide ^{177}Yb , ^{177}Lu of very high radioisomeric and radionuclidic purity may be produced.

The disadvantage in the choice of such a strategy, however, is the necessary radiochemical method for separating the Yb(macro)/¹⁷⁷Lu(micro) system. As the object nuclide and the target nuclide are two neighboring elements in the lanthanide group, the separation remains very demanding due to their chemical similarity.

5

An approach to the solution of the separation problem addressed above is to be found in the patent US 6,716,353 B1 which describes the separation of ¹⁷⁷Lu n.c.a. from ytterbium using the indirect way in accordance with the above-indicated equation (2) in order to thus produce ¹⁷⁷Lu with a high specific activity. In so doing, ytterbium, through the use of moderately concentrated mineral acids, initially is adsorbed by an LN resin which includes Di-(2-ethylhexyl) orthophosphoric acid (HDEHP) as extractant (Ln Resin of Eichrom). According to the method of US 6,716,353 B1, first ytterbium is eluted from an LN-resin containing chromatographic column using moderately concentrated hydrochloric acid, and subsequently ¹⁷⁷Lu is obtained by using higher concentrated hydrochloric acid.

10

15

Due to the fact that microscopic amounts of ¹⁷⁷Lu are to be separated from macroscopic amounts of ytterbium, a disadvantage of this prior art method is to be seen in that in accordance with US 6,716,353 B1 first the macroscopic component is eluted of which an extreme surplus is present. Since spreading of the ytterbium by tailing at the end of a peak is a consequence of the extraction chromatographic system, the process is to be repeated several times in order to obtain a corresponding quality of ¹⁷⁷Lu n.c.a., wherein a residual amount of ¹⁷⁶Yb not to be neglected inevitably remains in the Lu eluate on account of the system. Moreover, in accordance with the prior art of US 6,716,353 B1 merely activity amounts in an MBq range are obtained. The method disclosed in US 6,716,353 B1 is an extraction chromatographic method, which means that an extractant is adsorbed on the surface of the column material that naturally is eluted in part with the desired ¹⁷⁷Lu, thus additionally chemically contaminating the product. Moreover, for the elution of ¹⁷⁷Lu a large amount of concentrated hydrochloric acid is required in which the product subsequently is present. Moreover, the method described in US 6,716,353 B1 is very

20

25

30

time-consuming and requires a process time of more than 16 hours on a single column. With the required repeating steps the production thus lasts several days.

Very high medicinal demands on the quality of the ^{177}Lu nuclide thus render
5 the manufacturing process and hence feasibility thereof more difficult.

However, a successful application of the radionuclide ^{177}Lu is determined by the specific activity of the nuclide [Bq/mg] to be obtained through the production as well as by the purity thereof. High specific activity of the radionuclide is required so
10 as to achieve a specific activity that is as high as possible and thus optimally applied amounts of the corresponding radiopharmaceutical. In case no high specific activity and purity is achieved, this may lead inter alia to an adverse effect in the production of the radiopharmaceutical or to the quality of the radiopharmaceutical itself.

Moreover, JP 2010 223827 discloses a separation or respectively purification method, for ^{177}Lu from $^{176}\text{Yb}_2\text{O}_3$ using a HPLC, wherein a hydrochloric solution of the irradiated $^{176}\text{Yb}_2\text{O}_3$ is previously purified via cation and chelate exchange, the cation
15 exchange step being followed moreover by an anion exchange step for the removal of Fe.

20

Furthermore, Hashimoto et al.: "Production of no-carrier-added ^{177}Lu via the $^{176}\text{Yb}(n,\gamma)^{177}\text{Yb} \rightarrow ^{177}\text{Lu}$ process", J Radioanal Nucl Ch. Vol. 255, No. 3, March 1, 2003, 575-579, describe a method of manufacturing essentially non-carrier-added high-purity ^{177}Lu compounds for medicinal purposes from ^{176}Yb compounds irradiated
25 with thermal neutrons, wherein the end products of neutron irradiation, which essentially include a mixture of ^{177}Lu and ^{176}Yb in a mass ratio of approximately $1:10^2$ to $1:10^{10}$, are used as base materials, and wherein Yb_2O_3 insoluble in water is converted into a soluble form by way of HCl.

30 Based on the closest prior art of Hashimoto et al. it therefore is an objective technical object of the present invention to provide a method for making non-carrier-

added high-purity ^{177}Lu (non carrier added [n.c.a.] ^{177}Lu) available on an industrial scale for medicinal purposes.

In terms of method, the object is solved by the features of claims 1 and 10,
5 and in view of the use, the object is solved by the features of claim 12.

In particular, the present invention relates to a method of manufacturing essentially non-carrier-added high purity ^{177}Lu compounds for therapeutic and/or diagnostic purposes from ^{176}Yb compounds irradiated with thermal neutrons, wherein
10 the end products of neutron irradiation, which essentially contain a mixture of the nuclides ^{177}Lu and ^{176}Yb in an approximate mass ratio of $1:10^2$ to $1:10^{10}$, are used as base materials, wherein base materials that are insoluble in water, are converted into a soluble form possibly by way of mineral acids and/or increased temperature, and wherein the method comprises the following steps:

15

a) loading a first column packed with cation exchange material, with the base materials solved in mineral acid and containing ^{177}Lu and ^{176}Yb in an approximate mass ratio of $1:10^2$ to $1:10^{10}$; exchanging the protons of the cation exchange material for ammonium ions, thereby using an NH_4Cl
20 solution; and washing the cation exchange material of the first column with water;

b) linking the outlet of the first column with the inlet of a second column that likewise is packed with a cation exchange material;

25

c) applying a gradient of water and a chelating agent selected from the group consisting of: α -hydroxyisobutyrate [HIBA], citric acid, citrate, butyric acid, butyrate, EDTA, EGTA and ammonium ions, starting at 100% of H_2O to 0.2 M of the chelating agent on the inlet of the first column, so as to elute ^{177}Lu
30 compounds from the first and second column;

d) determining the radioactivity dose on the outlet of the second column in order to recognize the elution of ^{177}Lu compounds; and collecting a first ^{177}Lu eluate from the outlet of the second column in a vessel; and protonating the chelating agent so as to inactivate the same for the complex formation with ^{177}Lu ions;

e) loading a final separation column packed with a cation exchange material by continuously conveying the acidic ^{177}Lu eluate of step d) to the inlet of the final column; washing out the chelating agent with diluted mineral acid of a concentration lower than approximately 0.1 M; removing traces of other metal ions from the ^{177}Lu solution by washing the cation exchange material of the final column with mineral acid of various concentrations in a range of approximately 0.1 to 2.5 M;

f) eluting the ^{177}Lu ions from the final separation column by way of a highly concentrated mineral acid of approximately 3M to 12M; collecting the high purity ^{177}Lu eluate in a vaporizer unit and removing the mineral acid by vaporization.

The described embodiment may be repeated any number of times by repeating the separating method with α -hydroxyisobutyrate as chelating agent and the column systems described, as is described as an example in the following embodiment:

An alternative embodiment of the method in accordance with the invention is a method of manufacturing essentially non-carrier-added high-purity ^{177}Lu compounds for medicinal purposes from ^{176}Yb compounds irradiated with thermal neutrons, wherein the end products of neutron irradiation, which essentially contain a mixture of the nuclides ^{177}Lu and ^{176}Yb in an approximate mass ratio of $1:10^2$ to $1:10^{10}$, are used as base materials, wherein base materials that are insoluble in water, are converted into a soluble form by way of mineral acids and/or increased temperature, and wherein the method comprises the following steps:

- 5 a) loading a first column packed with cation exchange material, with the base materials solved in mineral acid and containing ^{177}Lu and ^{176}Yb in an approximate mass ratio of $1:10^2$ to $1:10^{10}$; exchanging the protons of the cation exchange material for ammonium ions, thereby using an NH_4Cl solution; and washing the cation exchange material of the first column with water;
- 10 b) linking the outlet of the first column with the inlet of a second column that likewise is packed with a cation exchange material;
- 15 c) applying a gradient of water and a chelating agent selected from the group consisting of: α -hydroxyisobutyrate [HIBA], citric acid, citrate, butyric acid, butyrate, EDTA, EGTA and ammonium ions, starting at 100% of H_2O to 0.2 M of the chelating agent on the inlet of the first column;
- 20 d) determining the radioactivity dose on the outlet of the second column in order to recognize the elution of ^{177}Lu compounds; and collecting a first ^{177}Lu eluate from the outlet of the second column in a vessel; and protonating the chelating agent so as to inactivate the same for the complex formation with ^{177}Lu ions;
- 25 e) continuously conveying the acidic ^{177}Lu eluate of step d) to the inlet of a third column packed with cation exchange material, the cation exchange material being present in protonated form due to the loading with acidic ^{177}Lu eluate; exchanging the protons of the cation exchange material for ammonium ions, thereby using an NH_4Cl solution; and washing the cation exchange material of the third column with water;
- 30 f) linking the outlet of the third column with the inlet of a fourth column packed with a cation exchange material;

g) applying a gradient of water and a chelating agent selected from the group consisting of: α -hydroxyisobutyrate [HIBA], citric acid, citrate, butyric acid, butyrate, EDTA, EGTA and ammonium ions, starting at 100% of H₂O to 0.2 M of the chelating agent, on the inlet of the third column;

5

h) determining the radioactivity dose on the outlet of the fourth column in order to recognize the elution of ¹⁷⁷Lu compounds; and collecting a second ¹⁷⁷Lu eluate from the outlet of the fourth column in a vessel; and protonating the chelating agent so as to inactivate the same for the complex formation with ¹⁷⁷Lu ions;

10

i) loading a final column packed with a cation exchange material by continuously conveying the acidic ¹⁷⁷Lu eluate of step h) to the inlet of the final column; washing out the chelating agent with diluted mineral acid; removing traces of other metal ions from the ¹⁷⁷Lu solution by washing the cation exchange material of the final column with mineral acid of various concentrations in a range of approximately 0.01 to 2.5 M;

15

j) eluting the ¹⁷⁷Lu ions from the final column by way of a concentrated mineral acid of approximately 1 M up to approximately 12M; collecting the high purity ¹⁷⁷Lu eluate in a vaporizer unit and removing the mineral acid by vaporization.

20

Although the prior art in accordance with "Lehrbuch der Anorganischen Chemie" (textbook of inorganic chemistry) of Hollemann-Wieberg, Publishers Walter de Gruyter, Berlin-New York, 102nd edition, 2007, pages 1932 to 1933, has long disclosed the basic principle of separating lanthanides and particularly trivalent lanthanides on the basis of cation exchange and complexation, this merely holds for the existence of similar amounts of lanthanides and not for mass ratios in which the desired lanthanide cation of highest purity has to be isolated from a millionfold mass-related surplus of another lanthanide. Moreover, even from the prior art in accordance with Hollemann-Wieberg, particularly from fig. 393, merely an insufficient selectivity between Lu and Yb is to be discerned, as both peaks significantly overlap

25

30

upon performing elution of the lanthanides from the ion exchange resin Dowex-50 with ammonium α -hydroxyisobutyrate in a mixture of the lanthanides Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu.

- 5 In contrast to the methods described in the prior art, the present invention makes it possible for the first time to manufacture industrially relevant quantities of high-purity non-carrier-added ^{177}Lu so that direct further processing, such as, for example, coupling to biomolecules for the manufacture of radio-pharmaceuticals, may be performed. This is in particular due to the fact that the demands for purity and sterility
10 on the obtained ^{177}Lu product are provided and that the method is fully compatible with EU-GMP guidelines.

A particular advantage of the manufacturing method in accordance with the present invention is that ytterbium may be processed in gram amounts. This makes the
15 production of several terabecquerel (TBq) of ^{177}Lu n.c.a. per production run possible. The manufacturing process thus for the first time enables the production of milligram amounts of the radionuclide ^{177}Lu n.c.a. which, on account of its chemical and radiochemical purity, is suited for the use in nuclear medicine and diagnostics.

- 20 A further advantage of the method in accordance with the invention resides in that it can be performed within approximately 10 hours until the final product is obtained.

This is due to several factors. On the one hand, many processes run simultaneously and thus, through the pre-column systems VS1 and VS2 (cf. fig. 1) used in a
25 preferred embodiment, the processes of the respective subsequent separations may be started even while the previous separation is still running. Furthermore, the gradients of the pumps may be optimized to high separating factors and short retention times for ^{177}Lu .

- 30 If, e.g., pre-columns are used, this enables, for example, the loading of cation exchange material with acidic or acidified solutions which basically would not be optimally suited for separation. Thus, complex process steps such as vaporizing or

neutralizing may be omitted at least to a great extent. Moreover, corrosion of the production plant is avoided in that no aggressive vapors occur through additional vaporizing steps. In addition, the risk of contamination is clearly reduced. By washing the pre-columns, contaminants can be removed from the system and, if need be,
5 suitably be disposed of or recycled.

The use of pre-columns generally improves the separation of the desired ^{177}Lu from Yb, and through a final purification step with a further column, the quality is further enhanced, as even traces of other metals may be removed thereby from the ^{177}Lu
10 product. Moreover, the method in accordance with the invention enables the provision of an already sterile end product, which in addition is virtually free of toxins and which can be used directly for radio-pharmaceutical further processing, e.g. coupling to proteins.

15 The dimensioning of such pre-columns and separation columns with regard to their geometrical dimensions and the dimension ratios thereof among one another is well known to a person skilled in the art.

Preferably, the method in accordance with the invention is performed according to
20 the following alternative embodiment: between steps d) and f) in accordance with claim 1, the following steps are performed additionally:

d.1) continuously conveying and at the same time acidifying the ^{177}Lu eluate of step d) to the inlet of a third column packed with a cation exchange material,
25 the cation exchange material being present in protonated form due to the loading with acidic ^{177}Lu eluate; exchanging the protons of the cation exchange material for ammonium ions, thereby using an NH_4Cl solution; and washing the cation exchange material of the third column with water;

30 d.2) linking the outlet of the third column with the inlet of a fourth column packed with a cation exchange material;

d.3) applying a gradient of water and a chelating agent selected from the group consisting of: α -hydroxyisobutyrate [HIBA], citric acid, citrate, butyric acid, butyrate, EDTA, EGTA and ammonium ions, starting at 100% of H₂O to 0.2 M of the chelating agent, on the inlet of the third column so as to elute ¹⁷⁷Lu compounds from the third and fourth column;

d.4) determining the radioactivity dose on the outlet of the fourth column in order to recognize the elution of ¹⁷⁷Lu compounds; and collecting a second ¹⁷⁷Lu eluate from the outlet of the third column in a vessel; and protonating the chelating agent so as to inactivate the same for the complex formation with ¹⁷⁷Lu ions.

The advantage of such an approach resides in that with two pairs of columns respectively connected consecutively in a process direction, one pre-column and one separation column each are provided. After running through the second pair of pre-column and separation column, the twofold purified ¹⁷⁷Lu eluate is then applied onto a final separation column and is further liberated of further traces of metal.

Furthermore, the concept of pre-columns/separation columns also has the advantage that a column application of acidic and acidified solutions, respectively, which in and for themselves would merely be partly suited for separation, is thereby made possible. The actual sharp separation is performed not until the separation column, i.e., for example, the second and/or fourth column. A further advantage is a reduced process time on account of quicker possible loading of the smaller pre-columns.

Of course, it is well known to a person skilled in the art that also more than two pairs of pre-columns/separation columns may be used, if need be.

With regard to recycling of the Yb materials used and of a reduced process time, it is advantageous if after elution of the ¹⁷⁷Lu compounds in steps d) and d.4) the first and second column and the third and fourth column are washed using higher concentrations of chelating agents so as to elute Yb ions from the cation exchange material, and Yb eluates obtained that essentially contain ¹⁷⁶Yb ions, are collected

separately for the purpose of re-using them as base material for the manufacture of ^{177}Lu .

5 The following mineral acids for acidifying the ^{177}Lu eluate have turned out to be suitable: HNO_3 , HCl , H_2SO_4 , HF , as well as organic acids such as, for example, acetic acid.

10 Provided that ^{177}Lu compounds are to be gained from ^{176}Yb oxides insoluble in water, it is possible and preferred to convert those oxides into a water-soluble form, e.g. by using 1M to 12M of HNO_3 or other oxidizing acids.

Typically, loading of the cation exchange materials is done using an acid concentration of 0.01 M to 2 M of HNO_3 , HCl or other inorganic and/or organic acids.

15 A cation exchange material selected from the group consisting of: macroporous and gel-like cation exchange resins on a polystyrene basis or on the basis of other organic polymers as well as cation exchange resins on a silicate basis has turned out to be particularly suited.

20 Other than in the prior art, preferably gram amounts of Yb base materials may be used and up to milligram amounts of ^{177}Lu may be produced.

25 Typically, the yields are at several TBq of ^{177}Lu and specific activities of approximately 3.9 TBq of ^{177}Lu /mg of lutetium may be obtained, which are close to reaching the theoretical physical limit of 4 TBq of ^{177}Lu /mg of ^{177}Lu .

For reasons of radiation protection as well as for reasons of pharmaceutical legislation, the present method is performed in a hot cell of at least clean-room class C in accordance with EU-GMP regulations.

30

In order to ensure the pharmaceutical quality of the non-carrier-added ^{177}Lu product and to obtain the manufacturing authorization, the chromatographic apparatus for

performing the method in accordance with the invention was transferred to the environment of a clean room. Moreover, the use of a hot cell also makes it possible to perform the method in accordance with the invention in form of a semi-automatic or fully automatic process.

5

Finally, the method in accordance with the invention results in a non-carrier-added ^{177}Lu compound (^{177}Lu n.c.a), the ^{177}Lu compound being obtained according to at least one of the methods in accordance with claims 1 to 11.

10 A particular advantage of the non-carrier-added ^{177}Lu compound is that it is suited directly for radiopharmaceutical use, i.e. without requiring further purification and/or sterilization.

With the ^{177}Lu compound produced according to the method in accordance with the
15 invention, a marking ratio of more than 400 MBq of ^{177}Lu per μg of peptide or polypeptide or other biomolecules may be reached.

A further advantage of the non-carrier-added ^{177}Lu compound produced in accordance with the invention is that it may still be used for marking peptides,
20 polypeptides, antibodies or other biomolecules even several weeks after its manufacture. This is particularly due to its high specific activity and its high radioisotopic and chemical purity.

With the method in accordance with the invention routine production of n.c.a.
25 ^{177}Lu in industrial amounts could be established for the first time.

Further advantages and features are to be seen from the description of an example and from the drawings:

30 Fig. 1 shows a schematic structure of an exemplary apparatus for performing the method in accordance with the invention;

Fig. 2 shows a column chromatogram of the separation of ^{177}Lu and ytterbium, recorded on the outlet of column S1 of fig. 1;

Fig. 3 shows a column chromatogram of the further separation of ^{177}Lu and ytterbium, recorded on the outlet of column S2 of fig. 1; and

Fig. 4 shows an SF-ICP mass spectrum of the non-carrier-added ^{177}Lu end product (n.c.a. ^{177}Lu) obtained in accordance with the invention as compared to c.a. ^{177}Lu in accordance with the prior art.

In the following, the exemplary structure of an apparatus for performing the method in accordance with the invention is described, thereby referring to fig. 1:

For reasons of radiation protection, the process is performed in an environment shielded by lead and/or plexiglass. This may be a hot cell or a different suitable system. In view of the fact that the product is used as pharmaceutical agent, the environment is to be classified into corresponding cleanliness classes in accordance with the demands of pharmaceutical manufacture (good manufacturing practice, GMP of the EU). In this case, the ambient condition in the hot cell has to conform to class C or higher.

The hot cell has suitable double door systems to the environment where auxiliary systems for production, such as HPLC pumps, syringe pumps or other conveying systems, and the control system are accommodated.

The system has several individual components such as chromatographic columns (VS1, S1, VS2, S2 and S3), flasks (F1 to F6) and pumps (P1 to P7) that are connected with each other via capillaries and valves.

Depending on their function, the pumps may be configured as vacuum pumps, syringe pumps, HPLC pumps, peristaltic pumps, or according to other principles of operation. In the present example, the pumps (P1) and (P2) are configured as HPLC

pumps. They convey different concentrations (from 0.01 M to 10 M) and flow rates (from 0.05 ml/min to 100 ml/min) of H₂O, HIBA and NH₄Cl. The pumps (P3), (P4), (P5), (P6) convey different concentrations (from 0.01 M to 10 M) and flow rates (from 0.05 ml/min to 100 ml/min) of further reagents such as HCl, HNO₃, H₂O and air. In the preferred configuration, pumps P3 to P6 are syringe pumps or plunger pumps. However, they may be implemented by further valves to form a pump system in the configuration of a syringe pump. Pump 7 (P7) is a vacuum pump configured to be able to apply a variable negative pressure (from 1 mbar to 1000 mbar) to the system.

10 The components marked by (N2) (without numbers of their own) are inert gas sources, preferably nitrogen or argon, through which pressure of between 0.1 bar to 5 bar or even higher, depending on the configuration of the system, can be applied to the system.

15 Component (1) is configured for breaking ampoules and in addition for the conversion of ytterbium oxide into ytterbium nitrate. In this example, the two separate functions are configured as integration of functions.

 Component (2) is a vaporizer unit for drying up the lutetium solution.

20 Component (3) is a system for accommodating the final product, such as, for example, a glass vial. Within the scope of an integration of functions, the components (2) and (3) can be configured as one structural component.

 All valves in the example are depicted so as to be switchable in each direction.

25 The position of the valves is selected so that the number thereof is minimized. As is obvious to a person of average skill from fig. 1, other valve configurations, particularly for joining or separating functions, are easily conceivable.

 Flasks (F1), (F2), (F3), (F4), (F5), (F6) are containers for receiving solutions.

30 Preferred embodiments are flasks of glass having a volume adapted to the requirements of the method in accordance with the invention. Particularly for larger volumes the preferred embodiment is a plastic container.

The column system exemplarily shown in the preferred embodiment comprises so-called pre-columns (VS 1) and (VS 2) through which loading is carried out. The main columns (S1) and (S2) which in the example form the actual separation columns are attached to the pre-columns, so that the respective partner columns (VS1) and (S1) or (VS2) and (S2) can be connected to form a column system.

The entire fluid scheme of the exemplary apparatus for performing the invention is depicted in fig. 1, irrespective of the actual configuration, also including the configuration within hot cells. A preferred embodiment is the positioning of components (2) and (3) in a separate shielded device so as to enable the follow-up process, i.e. filling up the amounts of ^{177}Lu intended for the customer, all in one device. For logical reasons, the components (2) and (3) are integrated in one system. A further preferred embodiment is the location of component (3) in a separate shielded unit, so that the entire process takes place in one unit and merely the vial (3) for receiving the product is positioned in a pharmaceutically more sophisticated environment.

For control of the process, activity sensors are used in the example that each are positioned at the end of columns (S1), (S2) and (S3) in order to monitor the process of separation.

Example

The present invention is a manufacturing process in which ^{177}Lu n.c.a. is extracted from reactor-irradiated ^{176}Yb . For this purpose, the irradiated ampoule is opened in an ampoule cup and transferred into a conversion vessel (F1). The ^{176}Yb may be present as insoluble oxide. For the extraction of the ^{177}Lu that occurred during irradiation, the base material has to be converted into a soluble form. In the present example, this may be achieved by the use of 1 M to 12 M of HNO_3 , if need be, by heating.

Through the dilution to a lower acid concentration of between 0.01 M and 1.5 M of HNO_3 , the solution can be loaded onto a pre-column system (VS1) as first column. By loading, the column material, a macroporous cation exchanger on a polystyrene basis, of the pre-column system is converted into a negative H^+ form (protonated form) for separation. Through the use of NH_4Cl , the column material of the pre-column system is converted into its NH_4^+ form. Subsequently, the pre-column system VS1 is washed with water and connected with the separation column S1 as second column.

Separation is conducted by way of the pump P1 at high flow rates (10-50 ml/min). For this purpose, a gradient of water and of α -hydroxy-isobutyrate (HIBA) used as chelating agent in the example, which is optimized for the separation in a VS1/S1 system, is set based on 100% of H_2O to 0.2 M of HIBA and separation is run through the pre-column system VS1 and the separation column S1. The separation is monitored by way of dose rate sensors. As soon as the ^{177}Lu is eluted from the column S1, the eluate is collected in the collection flask F2.

The separation of ^{177}Lu and ytterbium is depicted as a chromatogram in fig. 2. The ordinate indicates the eluted % amount of the ^{177}Lu and ytterbium, respectively, applied onto the column while the abscissa indicates the retention time in minutes. The massive peak rise of the ytterbium is due to the fact that shortly after a maximum of the lutetium peak, a shift was made to a high concentration of HIBA, so that the ytterbium can be obtained within a reasonable time and in an acceptable volume.

The chelating agent still contained in the eluate of column S1, HIBA in the present example, is protonated through the addition of acid and thus is rendered inactive. After the ^{177}Lu has been collected, the ytterbium is eluted from the first and second column through the use of higher concentrated HIBA and collected separately for the purpose of recycling.

Through addition of an acid into F2, the eluate of S1 can be retained in a second pre-column system VS2. In the example, the eluate is applied through

nitrogen pressure to the pre-column system VS2 as third column while further eluate is still being collected. In so doing, the addition of an acid into the flask F2 is required either at regular intervals or continuously. Upon loading, the column material of the system VS2 likewise is converted into its H^+ form. For conversion of the undesired H^+ form into the NH_4^+ form preferred for the separation, the VS2 system is washed with NH_4Cl and subsequently with water. The pre-column system VS2 is then connected with the separation column S2 as fourth column.

Further separation is conducted by way of an HPLC pump P2 at medium flow rates (1-10 ml/min). For this purpose, a gradient of water and HIBA optimized for separation in a VS2/S2 system as mentioned above is set and separation is run through the pre-column system VS2 and the separation column S2.

The separation is monitored by way of dose rate sensors. As soon as the ^{177}Lu is eluted from the column S2, the eluate is collected in the collection flask F3. The chelating agent HIBA still contained in the eluate, is protonated through the addition of acid and thus is rendered inactive. After the ^{177}Lu has been collected, the ytterbium is eluted from columns VS2 and S2 through the use of higher concentrated HIBA, and collected separately for the purpose of recycling.

Fig. 3 shows a section of a column chromatogram on column S2 in which again the dose rate is plotted against the retention time in minutes. Similar to fig. 2, the ytterbium peak (now merely being very small) in fig. 3 only appears to be shortly (with a retention time of approximately 135 min) after the lutetium peak, as shortly after the maximum of the lutetium peak (approximately 115 min) a shift to a high concentration of HIBA was made. Otherwise, during the separation the ytterbium would appear only after several hours, which would unnecessarily retard the process since it is, of course, reasonable to recycle the ytterbium, in particular ^{176}Yb .

The eluate of column S2 is loaded from the collection flask F3 to a final column S3 as fifth column. For this purpose, while still being collected, the eluate is applied through nitrogen pressure from the collection flask F3 to column S3. In so

doing, the addition of an acid into the flask F3 is required at regular intervals. After terminating loading of the final separation column S3, the column is liberated of HIBA by washing with diluted acid. Through selectively washing the column S3 with acid of various concentrations, further separation of traces and impurities, respectively, of other metals is made possible.

After final purification on the column S3, the ^{177}Lu is eluted into a vaporizer unit 2 by way of highly concentrated acid. The acid is removed through vaporization. The step also serves for sterilizing the end product at the same time.

The ^{177}Lu n.c.a. can now be absorbed in the desired solvent and in the desired concentration. After a final determination of the activity obtained and a quality check, the produced ^{177}Lu is filled into a vial 3 according to customer requirements.

Typically, the non-carrier-added ^{177}Lu compound obtained by way of the present method is characterized in that in an SF-ICP mass spectrum it merely exhibits a peak at an atomic mass of 177, whereas c.a. ^{177}Lu essentially exhibits three main peaks at atomic mass units of 175, 176 and 177. This difference is shown in the mass spectrum of fig. 4. The ordinate indicates the isotope distribution on a scale of relative frequency of 0 to 12. With the abscissa of fig. 4 the atomic mass is indicated. The mass-spectroscopic method used was the sector field mass spectrometry with inductively coupled plasma [Sector Field Inductively Coupled Plasma – Mass Spectrometry, SF-ICP-MS].

Patentkrav

1. Fremgangsmåde til fremstilling af i det væsentlige bærerfrie, ekstremt rene ^{177}Lu -forbindelser til medicinske formål ud fra ^{176}Yb -forbindelser, der er be-
5 strålet med termiske neutroner, hvor slutprodukterne fra neutronbestrålingen, som i det væsentlige indeholder en blanding af ^{177}Lu og ^{176}Yb i et massforhold på ca. $1:10^2$ til $1:10^{10}$, anvendes som udgangsmaterialer, hvor udgangsmaterialer, der er opløselige i vand, ved hjælp af mineralsyrer overføres til en opløselig form, og hvor fremgangsmåden omfatter de følgende trin:
- 10 a) at lade en første søjle (VS1), som er pakket med et kationudvekslingsmateriale, med de i mineralsyre opløste udgangsmaterialer, som indeholder ^{177}Lu og ^{176}Yb i et masseforhold på ca. $1:10^2$ til $1:10^{10}$; at udveksle protonerne fra kationudvekslingsmaterialet med ammoniumioner under anvendelse af
15 en NH_4Cl -opløsning; og at vaske kationudvekslingsmaterialet fra den første søjle (VS1) med vand;
- b) at forbinde udgangen af den første søjle (VS1) med indgangen af en anden søjle (S1), som ligeledes er pakket med et kationudvekslingsmateriale;
- 20 c) at anlægge en gradient af vand og en kompleksdanner, udvalgt fra gruppen bestående af: α -hydroxyisobutyrat [HIBA], citronsyre, citrat, smørsyre, butyrat, EDTA, EGTA og ammoniumioner, begyndende ved 100 % H_2O til 0,2 M kompleksdanner ved indgangen af den første søjle (VS1), for at eluere
25 ^{177}Lu -forbindelser fra den første (VS1) og den anden søjle (S1);
- d) at registrere radioaktivitetsdosen ved udgangen af den anden søjle (S1) for at genkende en eluering af ^{177}Lu -forbindelser; og at opfange et første ^{177}Lu -eluat fra udgangen af den anden søjle (S1) i et kar (F2); og at protonere
30 kompleksdanneren for at gøre denne uvirksom for kompleksdannelsen med ^{177}Lu -ioner;
- e) at lade en sidste separationssøjle (S3), som er pakket med et kationudvekslingsmateriale, ved kontinuerligt at lede det sure ^{177}Lu -eluat fra trin d)
35 videre til indgangen af den sidste separationssøjle (S3); at udvaske kom-

pleksdanneren med fortyndet mineralsyre med en koncentration på mindre end ca. 0,1 M; at fjerne fremmedmetalionspor fra ^{177}Lu -opløsningen ved at vaske kationudvekslingsmaterialet fra den sidste separationssøjle (S3) med mineralsyre med forskellige koncentrationer i området fra ca. 0,1 til 2,5 M;

5

f) at eluere ^{177}Lu -ionerne fra den sidste separationssøjle (S3) ved hjælp af en højkoncentreret mineralsyre på ca. 3 til 12 M; at opfange det ekstremt rene ^{177}Lu -eluat i en fordamperindretning og at fjerne mineralsyren ved fordampning.

10

2. Fremgangsmåde ifølge krav 1, **kendetegnet ved, at** der mellem trinnene d) og f) yderligere udføres de følgende trin:

d.1) kontinuert at lede det sure ^{177}Lu -eluat fra trin d) videre til indgangen af en tredje søjle (VS2), som er pakket med et kationudvekslingsmateriale, hvor kationudvekslingsmaterialet som følge af ladningen med det sure ^{177}Lu -eluat foreligger i protoneret form; at udveksle protonerne af kationudvekslingsmaterialet med ammoniumioner under anvendelse af en NH_4Cl -opløsning; og at vaske kationudvekslingsmaterialet fra den tredje søjle (VS2) med vand;

20

d.2) at forbinde udgangen af den tredje søjle (VS2) med indgangen af en fjerde søjle (S2), som er pakket med et kationudvekslingsmateriale;

d.3) at anlægge en gradient af vand og en kompleksdanner udvalgt fra gruppen bestående af: α -hydroxyisobutyrat [HIBA], citronsyre, citrat, smørsyre, butyrat, EDTA, EGTA og ammoniumioner, begyndende ved 100 % H_2O til 0,2 M kompleksdanner ved indgangen af den tredje søjle (VS2), for at eluere ^{177}Lu -forbindelser fra den tredje søjle (VS2) og den fjerde søjle (S2);

30

d.4) at registrere radioaktivitetsdosen ved udgangen af den fjerde søjle (S2) for at genkende en elution af ^{177}Lu -forbindelserne; og at opfange et andet ^{177}Lu -eluat fra udgangen af den tredje søjle (S2) i et kar (F3); og at protonere kompleksdanneren for at gøre denne uvirksom for kompleksdannelsen med ^{177}Lu -ioner.

3. Fremgangsmåde ifølge krav 1 eller 2, **kendetegnet ved, at** den første (VS1) og anden (S1) søjle samt den tredje (VS2) og den fjerde (S2) søjle efter elutionen af ^{177}Lu -forbindelserne i trin d) og d.4) vaskes med højere
5 kompleksdannerkoncentrationer for at eluere Yb-ioner fra kationudvekslingsmaterialet; og opnåede Yb-eluater, som i det væsentlige indeholder ^{176}Yb -ioner, samles særskilt med henblik på at genanvende dem som udgangsmateriale for ^{177}Lu -fremstillingen.
- 10 4. Fremgangsmåde ifølge et af de foregående krav, **kendetegnet ved, at** der som syre anvendes HNO_3 , HCl , HF eller H_2SO_4 eller organiske syrer, især eddikesyre.
- 15 5. Fremgangsmåde ifølge et af de foregående krav, **kendetegnet ved, at** ^{176}Yb -oxider, der er uopløselige i vand, overføres til en vandopløselig form ved anvendelse af 1M til 12M HNO_3 , H_2SO_4 eller andre oxiderende syrer.
- 20 6. Fremgangsmåde ifølge et af de foregående krav, **kendetegnet ved, at** ladningen af kationudvekslingsmaterialerne foregår med en syrekonzentration på 0,01 M til 2 M HNO_3 , HCl , eller andre organiske og/eller organiske syrer.
- 25 7. Fremgangsmåde ifølge et af de foregående krav, **kendetegnet ved, at** kationudvekslingsmaterialet udvælges fra gruppen bestående af: makroporøse og gellignende kationudvekslingsharpikser på basis af organiske polymerer, især sådanne på polystyrenbasis; og kationudvekslingsharpikser på silikatbasis.
- 30 8. Fremgangsmåde ifølge et af de foregående krav, **kendetegnet ved, at** der anvendes grammængder af udgangsmaterialer og produceres milligrammængder af ^{177}Lu .
9. Fremgangsmåde ifølge et af de foregående krav, **kendetegnet ved, at** der opnås udbytter på flere TBq ^{177}Lu og specifikke aktiviteter på ca. 3,9 TBq

^{177}Lu pr. mg Lutetium.

10. Fremgangsmåde til fremstilling af i det væsentlige bærerfrie, ekstremt rene ^{177}Lu -forbindelser til medicinske formål og/eller diagnostiske formål ud fra ^{176}Yb -forbindelser, der er bestrålet med termiske neutroner, hvor slutprodukterne fra neutronbestrålingen, som i det væsentlige indeholder en blanding af ^{177}Lu og ^{176}Yb i et masseforhold på ca. $1:10^2$ til $1:10^{10}$, anvendes som udgangsmaterialer, hvor udgangsmaterialer, der er opløselige i vand, ved hjælp af mineralsyrer overføres til en opløselig form, og hvor fremgangsmåden omfatter de følgende trin:

a) at lade en første søjle (VS1), som er pakket med et kationudvekslingsmateriale, med de i mineralsyre opløste udgangsmaterialer, som indeholder ^{177}Lu og ^{176}Yb i et masseforhold på ca. $1:10^2$ til $1:10^{10}$; at udveksle protonerne fra kationudvekslingsmaterialet med ammoniumioner under anvendelse af en NH_4Cl -opløsning; og at vaske kationudvekslingsmaterialet fra den første søjle (VS1) med vand;

b) at forbinde udgangen af den første søjle (VS1) med indgangen af en anden søjle (S1), som ligeledes er pakket med et kationudvekslingsmateriale;

c) at anlægge en gradient af vand og en kompleksdanner, udvalgt fra gruppen bestående af: α -hydroxyisobutyrat [HIBA], citronsyre, citrat, smørsyre, butyrat, EDTA, EGTA og ammoniumioner, begyndende ved 100 % H_2O til 0,2 M kompleksdanner ved indgangen af den første søjle (VS1);

d) at registrere radioaktivitetsdosen ved udgangen af den anden søjle (S1) for at genkende en eluering af ^{177}Lu -forbindelser; og at opfange et første ^{177}Lu -eluat fra udgangen af den anden søjle (S1) i et kar (F2); og at protonere kompleksdanneren for at gøre denne uvirksom for kompleksdannelsen med ^{177}Lu -ioner;

e) kontinuerligt at lede det sure ^{177}Lu -eluat fra trin d) videre til indgangen af en tredje søjle (VS2), som er pakket med et kationudvekslingsmateriale, hvor kationudvekslingsmaterialet som følge af ladningen med det sure ^{177}Lu -eluat

foreligger i protoneret form; at udveksle protonerne fra kationudvekslingsmaterialet med ammoniumioner under anvendelse af en NH_4Cl -opløsning; og at vaske kationudvekslingsmaterialet fra den tredje søjle (VS2) med vand;

- 5 f) at forbinde udgangen af den tredje søjle (VS2) med indgangen af en fjerde søjle (S2), som er pakket med et kationudvekslingsmateriale;

- g) at anlægge en gradient af vand og en kompleksdanner, udvalgt fra gruppen bestående af: α -hydroxyisobutyrat [HIBA], citronsyre, citrat, smørsyre, butyrat, EDTA, EGTA og ammoniumioner, begyndende ved 100 % H_2O til 0,2 M kompleksdanner, ved indgangen af den tredje søjle (VS2);
- 10

- h) at registrere radioaktivitetsdosen ved udgangen af den fjerde søjle (S2) for at genkende en elution af ^{177}Lu -forbindelserne; og at opfange et andet ^{177}Lu -eluat fra udgangen af den tredje søjle (S2) i et kar (F3); og at protonere kompleksdanneren for at gøre denne uvirksom for kompleksdannelsen med ^{177}Lu -ioner;
- 15

- i) at lade en femte søjle (S3), som er pakket med et kationudvekslingsmateriale, ved kontinuerligt at lede det sure ^{177}Lu -eluat fra trin h) videre til indgangen af den femte søjle (S3); at udvaske kompleksdanneren med fortyndet mineralsyre; at fjerne fremmedmetalionspor fra ^{177}Lu -opløsningen ved at vaske kationudvekslingsmaterialet fra den femte søjle (S3) med mineralsyre med forskellige koncentrationer i området fra 0,1 til 2,5 M;
- 20

- j) at eluere ^{177}Lu -ionerne fra den femte søjle ved hjælp af en koncentreret mineralsyre på ca. 1 M til op til ca. 12 M; at opfange det ekstremt rene ^{177}Lu -eluat i en fordamperindretning og at fjerne mineralsyren ved fordampning.
- 25

- 30 **11.** Fremgangsmåde ifølge et af de foregående krav, **kendetegnet ved, at** den udføres i en varm celle fra klasse C i henhold til EU's GMP-retningslinjer.

- 12.** Anvendelse af en kationudvekslingskromatografi-søjle med en kationudvekslingsharpiks som stationær fase og en kompleksdanner som mobil fase til fremstilling af ekstremt rene, bærerfrie ^{177}Lu -forbindelser i milligrammåle-
- 35

- stok fra en ^{176}Yb -matrix i grammålestok, hvor søjlen er pakket med et kation-udvekslingsmateriale, og protonerne fra kationudvekslingsmaterialet er blevet udvekslet med ammoniumioner under anvendelse af en NH_4Cl -opløsning; en gradient af vand og en kompleksdanner, udvalgt fra gruppen bestående af: α -hydroxyisobutyrat [HIBA], citronsyre, citrat, smørsyre, butyrat, EDTA, EGTA og ammoniumioner, begyndende ved 100 % H_2O til 0,2 M kompleksdanner, anlægges ved indgangen af søjlen; og en radioaktivitetsdosis registreres ved udgangen af søjlen for at genkende en eluering af ^{177}Lu -forbindelserne.
- 5




Fig. 2




Fig. 3




Fig. 4